BioSpace News Archive

NM-102, a novel next-generation microbiome modulator, shows positive effect in an aggressive immune checkpoint inhibitor failure melanoma model

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in the Craig-Hallum Capital Group’s annual Alpha Select Conference on Tuesday November 17, 2020. The conference consists of one-on-one and small group meetings, which will t

Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA).

Multiple new analyses reinforce the clinical value of noninvasive strategies to identify and monitor patients with advanced fibrosis due to NASH

Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 14:40 p.m. GMT/9:40 a.m. ET. A live webcast of the p

Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be participating in the Jefferies Virtual London Healthcare Conference, which is being held November 17-19. Details of the presentation are as follows: Dat

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical implementation of its UltraPorator™ system, a device exclusive to Precigen for the scale-up of rapid and cost-effective decentralized manufacturing of UltraCAR-T® therapies.

Chesapeake Urology, has enrolled their first patient in the VESAIR Clinical Trial.

Accenture (NYSE: ACN) has helped the U.S. subsidiary of Swedish pharmaceutical company Orexo launch its first digital therapeutic, vorvida®, for patients in the United States dealing with problematic alcohol use

Company to host investor call Monday, November 16th at 8:30 a.m. Eastern regarding third quarter 2020 financials & business updates